OTCM
PZRXQ
Market cap1kUSD
Nov 03, Last price
0.00USD
Name
PZ Wind Down Inc
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
-43.73%
Revenues
0
-100.00%
Net income
-20m
L+172.97%
CFO
-10m
L+64.06%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
PhaseRx, Inc. is a biopharmaceutical company dedicated to developing treatments for inherited enzyme deficiencies affecting the liver. Its therapeutic strategy involves intracellular enzyme replacement, powered by its unique Hybrid mRNA technology platform, which facilitates the production of absent enzymes directly within the body's cells. The company's pipeline includes several programs targeting urea cycle disorders, such as PRX-OTC for ornithine transcarbamylase deficiency, PRX-ASL for argininosuccinate lyase deficiency, and PRX-ASS1 for argininosuccinate synthetase deficiency. Established in 2006, PhaseRx is headquartered in Seattle, Washington.
Key people
Sean Monahan
Vice President - Chemistry · since 2015
Mary Prieve
Vice President - Biology · since 2015
Gordon Brandt
Chief Medical Officer · since 2016
James Watson
Head of Corporate Development · since 2015
Robert Overell
President, Chief Executive Officer, Principal Accounting Officer, Secretary, Director · since 2017
Paul Johnson
Director · since 2015
Independent Director · since 2008
Independent Chairman of the Board · since 2008
Michelle Griffin
Independent Director · since 2016
Independent Director · since 2016
John Schmidt
Independent Director · since 2010
Legal address
C/O Corporation Service Company
2711 Centerville Road
Suite 400
Wilmington, DE 19808
US
2711 Centerville Road
Suite 400
Wilmington, DE 19808
US
Headquarters
410 West Harrison Street
Suite 300
Seattle, WA 98119
US
Suite 300
Seattle, WA 98119
US
Valuation
Title USD in thousands, except ratios and share amounts | FY |
|---|---|
| 2016‑12 | |
| Income | |
Revenues | |
Cost of revenue | |
Unusual Expense (Income) | |
NOPBT | |
NOPBT Margin | |
Operating Taxes | |
Tax Rate | |
NOPAT | |
Net income | |
Dividends | |
Dividend yield | |
Proceeds from repurchase of equity | |
BB yield | |
| Debt | |
Debt current | |
Long-term debt | |
Deferred revenue | |
Other long-term liabilities | |
Net debt | |
| Cash flow | |
Cash from operating activities | |
CAPEX | |
Cash from investing activities | |
Cash from financing activities | |
FCF | |
| Balance | |
Cash | |
Long term investments | |
Excess cash | |
Stockholders' equity | |
Invested Capital | |
ROIC | |
ROCE | |
| EV | |
Common stock shares outstanding | |
Price | |
Market cap | |
EV | |
EBITDA | |
EV/EBITDA | |
Interest | |
Interest/NOPBT | |